RedHill lands new orphan drug designation, looks to grow commercial portfolio
At a time when RedHill Biopharma (NASDAQ: RDHL) is looking to grow its commercial portfolio, the company has landed U.S. Food and Drug Administration Orphan Drug Designation for MESUPRON for the treatment of pancreatic cancer – a market for which sales are expected to be $1.6 billion this year.
Benefits of the designation include development incentives and tax credits, as well as potentially a prescription drug user fee waiver and seven-year exclusive marketing period, if MESUPRON is ultimately…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health Management | Marketing | Pancreas | Pancreatic Cancer | Pharmaceuticals